Navigation Links
Veracyte, Inc. to Announce Third Quarter 2013 Financial Results and Host Conference Call on Monday, November 25, 2013
Date:11/11/2013

the number of unnecessary surgeries by employing a proprietary 142-gene signature to preoperatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The clinical utility and cost effectiveness of the GEC have been demonstrated in studies published in peer-reviewed journals and the clinical validity of the GEC has been demonstrated in a study published in The New England Journal of Medicine in 2012. Since the commercial launch of Afirma in January 2011, Veracyte has processed over 50,000 FNA samples for evaluation using Afirma and has performed more than 10,000 GECs to resolve indeterminate cytopathology results. Veracyte has obtained positive coverage decisions for Afirma from Aetna, Humana, Medicare and UnitedHealthcare. Collectively, these payers represent more than 100 million covered lives. Afirma is marketed and sold in the United States through a global co-promotion agreement with Genzyme Corporation, a subsidiary of Sanofi. Veracyte estimates the global market for Afirma to be $800 million. The company intends to expand its molecular cytology franchise to other clinical areas and is in late biomarker discovery for its first product in pulmonology.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to the estimated size of the global market for Afirma and to our intent to expand our molecular cytology business into other clinical areas. Forward-looking statements are indicated by words such as "believes," "expects" and "intends," and involve risks and uncertainties, which could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to: our limited operating history and history of losses; our ability to increase
'/>"/>

SOURCE Veracyte
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Veracyte, Inc. Announces Pricing of Initial Public Offering
2. Harwood Feffer LLP Announces Investigation of Santarus, Inc.
3. Stason Pharmaceuticals Inc. announces Kansas City expansion, adds human health capabilities
4. Imprimis Pharmaceuticals, Inc. Announces Its Attendance at the American Academy of Ophthalmology in New Orleans, Nov. 16-19
5. IceCure Medical Ltd. announces treatment of first breast cancer patient using its IceSense3 Cryoablation System at John Wayne Cancer Institute
6. Intrexon Announces Third Quarter Financial Results
7. Misonix, Inc. Announces First Quarter Fiscal Year 2014 Financial Results
8. Pro-Dex, Inc. Announces Fiscal 2014 First Quarter Financial Results Conference Call And Webcast
9. DURECT Announces Proposed Public Offering of Common Stock
10. Cellular Biomedicine Group Announces November 07, 2013 as Voting Deadline for Its Annual Shareholder Meeting
11. Star Scientific Announces Leadership Transition, Acceleration of Plans for Submission of an IND to FDA for Pharmaceutical Version of Anatabine Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... June 29, 2015 , ... The Mesothelioma Applied Research Foundation ... support program. This discussion series is part of the Meso Foundation’s larger program ... affected by mesothelioma. , The six week discussion series is tailored to mesothelioma ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... the weekend edition of USA TODAY. This 12-page, glossy, full-color special section hit ... in highly targeted markets totaling approximately 450,000 copies, with an estimated readership of ...
(Date:6/29/2015)... ... June 29, 2015 , ... Lake ... Balboa Care Center”, showcasing its prestigious five-star, premium rating from Medicare. Medicare’s ratings ... Balboa views this rating as indicative of its commitment to providing patients with ...
(Date:6/29/2015)... ... June 29, 2015 , ... A state-of-the-art ... NewYork-Presbyterian/Weill Cornell Medical Center. The device is the first of its kind approved ... positive airway pressure (CPAP), the current standard of care for OSA. , Some ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... announces the Fresh Plus Diaper, a baby invention that makes parenthood less tiring ... projected to reach a market value of USD 52.2 billion in 2017," says ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Provides Support for Patients and Families 2Health News:Mesothelioma Organization Provides Support for Patients and Families 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:Lake Balboa Releases New Facility Video of Patient Testimonials 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5
... David Llewellyn of Peninsula College of Medicine and Dentistry ... Investigator Research Grant to further his dementia research. New ... applicants who are the most promising researchers who have ... Dr. Llewellyn is the only researcher in ...
... Home nursing visits are as safe and effective as ... medical researchers. "Generally, moms and babies are discharged from ... Ian Paul, M.D., professor of pediatrics and public health ... is scheduled, and they don,t always show up. This ...
... Scientists are reporting development of a fast, reliable new ... of food poisoning that comes from eating fish tainted ... warm waters. The report appears in ACS, journal ... that 20,000-60,000 people every year come down with ciguatera ...
... study accepted for publication in The Endocrine Society,s Journal ... of dairy foods and higher protein resulted in improvements in ... degradation in overweight and obese young women over 16 weeks ... shown that higher body weight is associated with greater bone ...
... seriously ill adults who received care from a medical ... less likely to report medical errors, test duplication, and ... Fund international survey of patients, experiences in the U.S. ... Health Affairs "Web First" article, the study also ...
... News) -- Astronauts who spend six months or more in ... of their eyes, causing their vision to become blurry, according ... these changes may be the result of prolonged exposure to ... other long-term manned space voyages. "In astronauts over age ...
Cached Medicine News:Health News:US grant exclusive for UK dementia researcher 2Health News:US grant exclusive for UK dementia researcher 3Health News:New mothers, newborns happy with home visits 2Health News:Fast new test for terrible form of food poisoning 2Health News:Dairy foods may improve bone health during diet and exercise in overweight premenopausal women 2Health News:New international health survey of sicker adults: Those with a medical home fare better 2Health News:New international health survey of sicker adults: Those with a medical home fare better 3Health News:New international health survey of sicker adults: Those with a medical home fare better 4Health News:New international health survey of sicker adults: Those with a medical home fare better 5Health News:Space Travel Might Lead to Eye Trouble: Study 2
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: